{"id":"anitocabtagene-autleucel","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Cytokine release syndrome"},{"rate":"10-30%","effect":"Neutropenia"},{"rate":"5-20%","effect":"Anemia"},{"rate":"5-20%","effect":"Thrombocytopenia"},{"rate":"5-20%","effect":"Infections"}]},"_chembl":{"chemblId":"CHEMBL5314723","moleculeType":"Gene"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This CAR T-cell therapy works by removing T-cells from a patient's blood, genetically modifying them to recognize and bind to BCMA on myeloma cells, and then reinfusing the modified T-cells to attack and kill the cancer cells. The BCMA-targeting CAR T-cells can induce a sustained anti-myeloma response and potentially lead to long-term remission.","oneSentence":"Anitocabtagene autleucel is a chimeric antigen receptor (CAR) T-cell therapy that targets the B-cell maturation antigen (BCMA) on multiple myeloma cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:09:34.982Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory multiple myeloma"}]},"trialDetails":[{"nctId":"NCT05041309","phase":"","title":"Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells","status":"ENROLLING_BY_INVITATION","sponsor":"Kite, A Gilead Company","startDate":"2021-12-15","conditions":"Solid and Hematological Malignancies","enrollment":1000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CART-ddBCMA"],"phase":"phase_2","status":"active","brandName":"Anitocabtagene autleucel","genericName":"Anitocabtagene autleucel","companyName":"Kite, A Gilead Company","companyId":"kite-a-gilead-company","modality":"Biologic","firstApprovalDate":"","aiSummary":"Anitocabtagene autleucel is a chimeric antigen receptor (CAR) T-cell therapy that targets the B-cell maturation antigen (BCMA) on multiple myeloma cells. Used for Relapsed or refractory multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}